Common use of Development Event Based Payments Clause in Contracts

Development Event Based Payments. If Roche (alone or with its Affiliates) develops a Non-Memory Compound for a Neurological Indication or a Psychiatric Indication, then Roche shall pay Memory for such Non-Memory Compound achieving the Events of Sections 4.3(a) and 4.3(b) as if such Non-Memory Compound were a Product except (i) Roche shall pay [*] percent ([*]%) of such payments related to IND, Phase II and Phase III Events, and (ii) [*] percent ([*]%) of all other payments provided under Section 4.3(a) and 4.3(b). If Roche (alone or with its Affiliates) develops a Non-Memory Compound for an Other Indication, then Roche shall pay Memory for such Non-Memory Compound achieving the Events of Sections 4.3(c) as if such Non-Memory Compound were a Product except (i) Roche shall pay [*] percent ([*]%) of such payments related to IND, Phase II and Phase III Events, and (ii) [*] percent ([*]%) of all other payments provided under Section 4.3(c). Each payment in this Schedule C shall be due and payable by Roche within thirty (30) days after occurrence of the applicable Event. Roche will make each of such payments only once, for the first occurrence of a respective Event, regardless of how many times the Event may be subsequently achieved with a Non-Memory Compound. An Event shall be deemed to have occurred regardless of whether a Product or a Non-Memory Compound first achieved the Event.